Rat Basophilic Leukemia Cells (RBL-2H3) Generate Prostaglandin D 2 (PGD 2 ) after Regulated upon Activation,Normal T-cell Expressed and Secreted (RANTES) activation
Free accessResearch articleFirst published online October, 2006
Rat Basophilic Leukemia Cells (RBL-2H3) Generate Prostaglandin D 2 (PGD 2 ) after Regulated upon Activation,Normal T-cell Expressed and Secreted (RANTES) activation
Increasing evidence indicates that local neurogenic inflammation, possibly in response to different stimuli, may be involved in sensory nerve sensitization, migraine generation and some other precipitating events leading to neuronal dysfunction in the brain. In addition, mast cells generate eicosanoids that are linked to asthma and other inflammatory diseases. Regulated upon activation, normal T-cell expressed and secreted (RANTES) is a small protein and a prototype member of the CC chemokine-beta subfamily with chemoattractant and inflammatory properties. In this study we used the RBL-2H3 cell line to determine whether or not these cells generate prostaglandin D2 (PGD2) after treatment with RANTES. After 4 hours of incubation, RBL-2H3 cells cultured with RANTES at 20 ng/mL released large amounts of PGD2 in a dose-response manner compared to control. Moreover, RBL-treated RANTES generated a large quantity of histamine. Our study confirms once again the proinflammatory action of RANTES, in this case acting on the stimulation of the arachidonic acid cascade product PGD2.
ContiP., PangX., BoucherW.Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase.Blood1997; 89: 4120–7.
2.
MoriiE., ObokiK.MITF is necessary for generation of prostaglandin D2 in mouse mast cells.J Biol Chem.2004; 279: 48923–9.
KielianT., McMahonM., BeardenE.D., BaldwinA.C., DrewP.D., EsenN.S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2).J Neurochem2004; 90: 1163–72.
5.
TheoharidesT.C., DonelanJ.M., PapadopoulouN., CaoJ., KempurajD., ContiP.Mast cells as targets of corticotropin-releasing factor and related peptides.Trends Pharmacol Sci2004; 25: 563–8.
6.
LesmaE., RivaE., GiovanniniM., Di GiulioA.M., GorioA.Amelioration of neutrophil membrane function underlies granulocyte-colony stimulating factor action in glycogen storage disease 1b.Int J Immunopathol Pharmacol2005; 18: 297–308.
7.
Di GiannantonioM., FrydasS., KempurajD.Cytokines in stress.Int J Immunopathol Pharmacol2005; 18: 1–6.
8.
AlexandrakisM.G., PassamF.H., PappaC.A.Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-α in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density.Int J Immunopathol Pharmacol2005; 18: 287–96.
9.
TrubianiO., GuarnieriS., OrcianiM., SalvoliniE., Di PrimioR.Sphingolipid microdomains mediate CD38 internalization: Topography of the endocytosis.Int J Immunopathol Pharmacol2004; 17: 293–300.
10.
Appert-CollinA., DuongF.H.T., Passilly DegraceP., WarterJ-M, PoindronP., GiesJ-P. MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden.Int J Immunopathol Pharmacol2005; 18: 21–32.
11.
TheoharidesT.C.Neuroimmunology of tumor growth: the role of mast cells.Int J Immunopathol Pharmacol1988; 1: 89–98.
12.
KempurajD., MadhappanB., SheeladeviR.T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors.Int J Immunopathol Pharmacol2004; 17: 57–64.
13.
AngeliV., StaumontD., CharbonnierA.S.Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses.J Immunol2004; 172: 3822–9.
14.
ShrivastavaP., SinghS.M., SinghN.Activation of tumor-associated macrophages by thymosin alpha 1.Int J Immunopathol Pharmacol2004; 17: 39–48.
15.
FrydasS., KaragouniE., HatzistilianouM.Chemokines and allergic disorders: a revised study.Int J Immunopathol Pharmacol2004; 17: 233–6.
16.
TheoharidesT.C., SantG.R.A pilot open label study of Cystoprotek(r) in interstitial cystitis.Int J Immunopathol Pharmacol2005; 18: 183–8.
17.
RidoloE., AlbertiniR., BorghiL., MeschiT., MontanariE., Dall'AglioPp. Acute polyradiculoneuropathy occurring after hymenoptera stings: a clinical case study.Int J Immunopathol Pharmacol2005; 18: 385–90.
18.
TotaroR., PassacantandoA., RussoT.Effects of interferon beta, cyclophosphamide, and azathioprine on cytokine profile in patients with multiple sclerosis.Int J Immunopathol Pharmacol2005; 18: 377–84.
19.
DemidovaT.N., HamblinM.R.Targeted photodynamic therapy to inflammatory cells and pathogens.Int J Immunopathol Pharmacol2004; 17: 117–26.
20.
ContiP., RealeM., BarbacaneR.C., LetourneauR., TheoharidesT.C.Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effect in genetically mast cell-deficient W/Wv mice.FASEB J1998; 12: 1693–700.
21.
TheoharidesT.C., ContiP.Mast cells: Jekyll and Hyde of tumor growth.Trends Immunol2004; 25: 235–41.
22.
HartP.H.Regulation of the inflammatory response in asthma by mast cell products.Immunol Cell Biol.2001; 79: 149–53.
23.
Sodin-SemrlS., SpagnoloA., BarbaroB., VargaJ., FioreS.Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes.Int J Immunopathol Pharmacol2004; 17: 15–25.
24.
CavalieriS., RotoliM., FelicianiC., AmerioP.Expression of the high-affinity laminin receptor (67 kDa) in normal human skin and appendages.Int J Immunopathol Pharmacol2005; 18: 223–32.
25.
KavA.B.Mediators of hypersensitivity and inflammatory cells in the pathogenesis of bronchial asthma.Eur J Respir Dis Suppl1983; 129: 1–44.
26.
GrittiD., MalinvernoA., GasparettoC., WiedermannC.J., RicevutiG.Attenuation of leukocyte [beta]2–integrin expression by antithrombin-III.Int J Immunopathol Pharmacol2004; 17: 27–32.
27.
RossiR.E., MonasteroloG.A pilot study of feasibility of ultra-rush (20–25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.Int J Immunopathol Pharmacol2005; 18: 277–86.
28.
KempurajD., HuangM., Kandere-GrzybowskaK.Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells.Int Arch Allergy Immunol2003; 132: 231–9.
29.
LicastroF., ChiappelliM., RuscicaM., CarnelliV., CorsiM.M.Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type.Int J Immunopathol Pharmacol2005; 18: 165–72.
30.
PannelliniT., IezziM., Di CarloE.The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis.Int J Immunopathol Pharmacol2004; 17: 171–80.
31.
MussoT., CappelloP., StornelloS.IL-10 enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes.Int J Immunopathol Pharmacol2005; 18: 339–50.
32.
KempurajD., FrydasS., KaragouniE.Cytokines and the brain.Int J Immunopathol Pharmacol2004; 17: 229–32.
33.
TheoharidesT.C.Mast cells and stress – A psychoneuroim-munological perspective.J Clin Psychopharmacol2002; 22: 103–8.
34.
DhabharF.S., MillerA.H., McEwenB.S., SpencerR.L.Stress-induced changes in blood leukocyte distribution. Role of adrenal steroid hormones.J Immunol1996; 157: 1638–44.
35.
ChiD.S., FitzgeraldS.M., PittsS.MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response.BMC Immunol2004; 5: 22.
36.
OppenheimJ.J., ZachariaeC.O.C., MukaidaN., MatsushimaK.Properties of the novel proinflammatory supergene “intercrine” cytokine family.Annu Rev Immunol1991; 9: 617–23.
37.
SchallT.J.Biology of the RANTES/SIS cytokine family.Cytokine1991; 3: 165–83.
38.
SchuligoiR., GrillM., HeinemannA., PeskarB.A., AmannR.Sequential induction of prostaglandin E and D synthases in inflammation.Biochem Biophys Res Commun2005; 333: 684–9.
39.
HritzI., MolnárB., TulassayZ., PrónaiL.Proton pump inhibitor co-therapy normalizes the increased cell turnover of the gastric mucosa both in NSAID and selective Cox-2 users.Int J Immunopathol Pharmacol2005; 18: 75–84.
40.
FrydasS., PapaioannouN., PapazahariadouM.Inhibition of MCP-1 and MIP-2 chemokines in murine trichinellosis: effect of the anti-inflammatory compound l-mimosine.Int J Immunopathol Pharmacol2005; 18: 85–94.
41.
KempurajD., DonelanJ., FrydasS.Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities.Int J Immunopathol Pharmacol2004; 17: 103–6.
42.
TanakaK., HiraiH., TakanoS., NakamuraM., NagataK.Effects of prostaglandin D2 on helper T cell functions.Biochem Biophys Res Commun2004; 316: 1009–14.
43.
MarchisioM., GrimleyP.M., Di BaldassarreA., SantavenereE., MisciaS.Novel shift of Jak/Stat signaling characterizes the protective effects of aurintricarboxylic acid (ATA) from tumor necrosis factor-alpha toxicity in human B lymphocytes.Int J Immunopathol Pharmacol2004; 17: 5–14.
44.
CrossM.L.Immune-signalling by orally-delivered probiotic bacteria: effects on common mucosal immunoresponses and protection at distal mucosal sites.Int J Immunopathol Pharmacol2004; 17: 127–36.
45.
GuidiL., CostanzoM., CiarnielloM.Increased levels of NF-kB inhibitors (IκBα and IκBγ) in the intestinal mucosa of Crohn's disease patients during infliximab treatment.Int J Immunopathol Pharmacol2005; 18: 155–64.
46.
YamakiK., UchidaH., LiX.Effect of varying types of anti-arthritic drugs on Th1 and Th2 immune responses in mice.Int J Immunopathol Pharmacol2005; 18: 133–44.
47.
CognasseF., ChavarinP., AcquariS.Differential downstream effects of ligation mediated by membrane or soluble CD40L and agnostic Ab: a study on purified human B cells.Int J Immunopathol Pharmacol2005; 18: 65–74.
48.
SommaP., Lo MuzioL., MansuetoG.Squamous cell carcinoma of the lower lip: Fas/FasL expression, lymphocyte subtypes and outcome.Int J Immunopathol Pharmacol2005; 18: 59–64.
49.
FalkensammerB., FasserW., SchererK.Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.Int J Immunopathol Pharmacol2005; 18: 145–54.
50.
MarchisioM., SabatinoG.M., AlbaneseA., SantavenereE., BuonaguidiR., MisciaS.Novel evidence of PLC delta2 involvement in the regulation of the differential evolution of human aneurysms.Int J Immunopathol Pharmacol2004; 17: 381–8.
51.
CenturioneL., Di GiulioC., SantavenereE.Protein kinase C ζ regulation of hypertrophic and apoptotic events occurring during rat neonatal heart development and growth.Int J Immunopathol Pharmacol2005; 18: 49–58.
52.
GhezziP., UngheriD.Synergistic combination of n-acetyl-cysteine and ribavirin to protect from lethal influenza viral infection in a mouse model.Int J Immunopathol Pharmacol2004; 17: 99–102.
53.
PetruzziM., De BenedittisM., LoriaM.P.Immune response in patients with oral lichen planus and HCV infection.Int J Immunopathol Pharmacol2004; 17: 93–8.
PetruzziM., De BenedittisM., LoriaM.P.Immune response in patients with oral lichen planus and HCV infection.Int J Immunopathol Pharmacol2004; 17: 93–8.
56.
GuayJ., BatemanK., GordonR., ManciniJ., RiendeauD.Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1.J Biol Chem2004; 279: 24866–72.
57.
LuoC., SimellO., KungH.F., HeM.L.Cox-2 expressed with insulin in pancreatic beta-cells, and in the infiltrated leukocytes in inflamed islets of diabetic mice.Eur J Inflamm2005; 3: 55–62.
58.
OgilvicA.L.J., LüftlM., AntoniC., SchulerG., KaldenJ.R., LorenzH-M. Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R p60 in psoriatic ski is driven by TNF-α.Int J Immunopathol Pharmacol2006; 19(2): 271–8.
59.
EmporiadouM., HatzistilianouM., HaidopoulouK.Procalcitonin and inflammatory cytokines in children with asthma.Eur J Inflamm2005; 3: 75–82.
